Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $221.00 price target on the stock. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2024 earnings at $1.81 EPS, FY2024 earnings at $3.64 EPS, FY2025 earnings at $5.57 EPS, FY2026 earnings at $7.02 EPS, FY2027 earnings at $9.34 EPS and FY2028 earnings at $9.76 EPS.

A number of other brokerages have also recently issued reports on KRYS. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Citigroup restated a “neutral” rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Chardan Capital increased their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Finally, William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and a consensus price target of $197.00.

Krystal Biotech Price Performance

KRYS opened at $185.45 on Tuesday. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The company has a market capitalization of $5.33 billion, a price-to-earnings ratio of 104.77 and a beta of 0.82. The firm’s fifty day moving average price is $181.20 and its two-hundred day moving average price is $180.29.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the previous year, the firm posted ($0.67) earnings per share. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. As a group, equities analysts anticipate that Krystal Biotech will post 2.88 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jamison Private Wealth Management Inc. purchased a new position in Krystal Biotech during the second quarter valued at $28,000. GAMMA Investing LLC lifted its position in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares during the period. Key Financial Inc bought a new stake in Krystal Biotech during the second quarter worth about $28,000. Blue Trust Inc. grew its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the period. Finally, Values First Advisors Inc. bought a new position in shares of Krystal Biotech during the third quarter valued at approximately $53,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).